BioWorld

Sep. 21, 2007

View Archived Issues

Peramivir Stumbles In Phase II Influenza Study; BioCryst Falls

Shares of BioCryst Pharmaceuticals Inc. tumbled more than 30 percent following a Phase II miss with the influenza drug peramivir, despite assurances from company executives that inadequate needle-lengths were to blame. (BioWorld Today) Read More

House Passes Long-Awaited Legislation On FDA Reform

Read More

NewCo News: ImmunoBiosciences Using ICV Platform To Improve Vaccines

Read More

Progenics Raises $57M Publicly; Cellerix Gets $40M In Series B

Read More

Other News To Note

Read More

ICAAC Roundup

Read More

Clinic Roundup

Read More